Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00087100 |
|
Recruitment Status :
Completed
First Posted : July 12, 2004
Last Update Posted : February 14, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Drugs used in chemotherapy such as pemetrexed disodium work in different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: This phase II trial is studying how well pemetrexed disodium works in treating patients with persistent or recurrent endometrial cancer.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Endometrial Cancer | Drug: pemetrexed disodium | Phase 2 |
OBJECTIVES:
- Determine the antitumor activity of pemetrexed disodium in patients with persistent or recurrent endometrial adenocarcinoma that failed higher priority treatment protocols.
- Determine the nature and degree of toxicity of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Beginning 7 days before and continuing until 3 weeks after the last dose of pemetrexed disodium, patients also receive oral folic acid daily and cyanocobalamin (vitamin B_12) intramuscularly every 9 weeks.
Patients are followed every 3 months for 2 years and then every 6 months for 3 years.
PROJECTED ACCRUAL: Approximately 19-51 patients will be accrued for this study within 1-3.4 years.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 51 participants |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase II Evaluation Of Pemetrexed (ALIMTA, LY231514, IND #40061) In The Treatment Of Recurrent Or Persistent Endometrial Carcinoma |
| Study Start Date : | May 2006 |
| Actual Primary Completion Date : | August 2007 |
- Antitumor activity
- Toxicity
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
-
Histologically confirmed endometrial adenocarcinoma
- Persistent or recurrent disease
- Refractory to curative or standard therapy
-
Measurable disease
- At least 1 unidimensionally measurable target lesion ≥ 20 mm by conventional techniques, including palpation, plain x-ray, CT scan, or MRI OR ≥ 10 mm by spiral CT scan
- Tumors within a previously irradiated field are considered non-target lesions unless progression is documented or biopsy is obtained to confirm persistence ≥ 90 days after completion of radiotherapy
-
Must have received 1 prior chemotherapy regimen for endometrial cancer
- Initial treatment may have included high-dose therapy, consolidation, or extended therapy administered after surgical or non-surgical assessment
- Not eligible for a higher priority GOG protocol (i.e., any active phase III GOG protocol for the same patient population)
PATIENT CHARACTERISTICS:
Age
- Any age
Performance status
- GOG 0-2
Life expectancy
- Not specified
Hematopoietic
- Absolute neutrophil count ≥ 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 9 g/dL
Hepatic
- AST and ALT ≤ 3 times upper limit of normal (ULN)*
- Alkaline phosphatase ≤ 3 times ULN*
- Bilirubin ≤ 1.5 times ULN NOTE: * ≤ 5 times ULN if liver metastases are present
Renal
- Creatinine clearance ≥ 45 mL/min
Other
- Not pregnant
- Negative pregnancy test
- Fertile patients must use effective contraception during and for at least 3 months after study participation
- Neuropathy (sensory and motor) ≤ grade 1
- No active infection requiring antibiotics
- No other invasive malignancy within the past 5 years except nonmelanoma skin cancer
PRIOR CONCURRENT THERAPY:
Biologic therapy
- At least 3 weeks since prior biologic or immunologic agents for the malignant tumor
-
One prior non-cytotoxic (biologic or cytostatic) regimen for recurrent or persistent disease allowed, including, but not limited to, the following:
- Monoclonal antibodies
- Cytokines
- Small-molecule inhibitors of signal transduction
- At least 24 hours since prior growth factors
- No concurrent routine colony-stimulating factors
Chemotherapy
- See Disease Characteristics
- Recovered from prior chemotherapy
- No more than 1 prior cytotoxic chemotherapy regimen with either single or combination cytotoxic drug therapy
- No prior pemetrexed disodium
Endocrine therapy
- At least 1 week since prior hormonal therapy directed at the malignant tumor
- Concurrent hormone replacement therapy allowed
Radiotherapy
- See Disease Characteristics
- At least 2 weeks since prior radiotherapy and recovered
- No prior radiotherapy to ≥ 25% of bone marrow
Surgery
- Recovered from prior surgery
Other
- At least 3 weeks since other prior therapy directed at the malignant tumor
-
No nonsteroidal anti-inflammatory drugs 2-5 days before, during, and for 1-2 days after study drug administration
- Concurrent daily low-dose (≤ 325 mg/day) aspirin therapy allowed
- No prior therapy that would contraindicate study participation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00087100
Show 23 study locations
| Study Chair: | David S. Miller, MD | Simmons Cancer Center |
| Responsible Party: | Gynecologic Oncology Group |
| ClinicalTrials.gov Identifier: | NCT00087100 |
| Other Study ID Numbers: |
GOG-0129O LILLY-H3E-US-JMGT CDR0000372921 |
| First Posted: | July 12, 2004 Key Record Dates |
| Last Update Posted: | February 14, 2014 |
| Last Verified: | February 2014 |
|
recurrent endometrial carcinoma endometrial adenocarcinoma stage III endometrial carcinoma stage IV endometrial carcinoma |
|
Endometrial Neoplasms Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms Uterine Diseases |
Pemetrexed Antineoplastic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors |